Browse Studies — Arctuva

Phase 2

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).

HLA-A*0201 Positive Cells PresentClear Cell Sarcoma (CCS)

Estimated

~$10 – $7,500

Sarcoma Alliance for Research through CollaborationNCT06942442

Phase 1

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free surviva…

Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+39 more

Phase 1

Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors

Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced t…

NeuroblastomaRhabdomyosarcomaSynovial Sarcoma+11 more

Estimated

~$10 – $6,250

University of FloridaNCT06625190

Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells gene…

Pediatric Solid TumorOsteosarcomaRhabdomyosarcoma+13 more

Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT04897321